📊 AUTL Key Takeaways
Is Autolus Therapeutics plc (AUTL) a Good Investment?
Autolus demonstrates impressive 644.9% YoY revenue growth from product commercialization, indicating market traction. However, the company operates at an unsustainable -273% net margin with -$68M annual free cash flow burn. At this trajectory, the $130.9M cash position provides only 18-24 months of runway, necessitating dilutive equity financing before achieving profitability.
Autolus Therapeutics shows headline revenue acceleration, but the quality of that growth appears weak relative to its economics because operating losses, net losses, and free cash outflow remain extremely large versus revenue. The balance sheet is a mitigating factor, with strong near-term liquidity and no meaningful leverage, but fundamentals still point to a business that has not yet demonstrated durable profitability or cash flow sustainability.
Autolus Therapeutics plc Key Strengths (AUTL)
- Exceptional 644.9% YoY revenue growth signals successful product commercialization and market adoption
- Strong liquidity position with $130.9M cash, 5.8x current ratio, and zero long-term debt eliminates near-term solvency risk
- Equity-financed capital structure avoids debt service obligations, preserving cash for operations and development
- Very strong liquidity with a 6.19x current ratio and 5.86x quick ratio
- Debt-free capital structure reduces refinancing and interest burden risk
- Revenue grew sharply year over year, indicating commercial or partnership traction
AUTL Stock Risks: Autolus Therapeutics plc Investment Risks
- Severe unprofitability with -273% net margin and -$59.5M operating loss on only $26.2M revenue is structurally unsustainable
- Negative free cash flow of -$68M annually implies 18-24 month cash runway, requiring dilutive equity financing within 12-24 months
- Biotech sector inherent risks including regulatory setbacks, clinical trial failures, competitive threats, and efficacy/safety concerns
- Operating margin of -387.6% and net margin of -385.9% show the business is still far from profitable
- Free cash flow of -$236.17M and operating cash flow of -$216.25M imply heavy ongoing cash burn
- Negative ROE of -74.3% and ROA of -29.8% indicate poor capital efficiency
Key Metrics to Watch
- Gross margin when disclosed - critical indicator of whether revenue scale improves unit economics and path to profitability
- Quarterly revenue growth rate - watch for inflection point where revenue growth accelerates relative to cost base
- Cash burn rate and cash position trajectory - determines financing need timing and magnitude of shareholder dilution risk
- Quarterly operating cash burn relative to cash and equivalents
- Whether revenue growth converts into materially improved operating margin and lower net losses
Autolus Therapeutics plc (AUTL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.80x current ratio provides a solid financial cushion.
AUTL Profit Margin, ROE & Profitability Analysis
AUTL vs Healthcare Sector: How Autolus Therapeutics plc Compares
How Autolus Therapeutics plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Autolus Therapeutics plc Stock Overvalued? AUTL Valuation Analysis 2026
Based on fundamental analysis, Autolus Therapeutics plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Autolus Therapeutics plc Balance Sheet: AUTL Debt, Cash & Liquidity
AUTL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Autolus Therapeutics plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.86 indicates the company is currently unprofitable.
AUTL Revenue Growth, EPS Growth & YoY Performance
AUTL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.0M | -$70.2M | $-0.26 |
| Q3 2025 | N/A | -$79.1M | $-0.30 |
| Q2 2025 | N/A | -$47.9M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Autolus Therapeutics plc Dividends, Buybacks & Capital Allocation
AUTL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Autolus Therapeutics plc (CIK: 0001730463)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AUTL
What is the AI rating for AUTL?
Autolus Therapeutics plc (AUTL) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AUTL's key strengths?
Claude: Exceptional 644.9% YoY revenue growth signals successful product commercialization and market adoption. Strong liquidity position with $130.9M cash, 5.8x current ratio, and zero long-term debt eliminates near-term solvency risk. ChatGPT: Very strong liquidity with a 6.19x current ratio and 5.86x quick ratio. Debt-free capital structure reduces refinancing and interest burden risk.
What are the risks of investing in AUTL?
Claude: Severe unprofitability with -273% net margin and -$59.5M operating loss on only $26.2M revenue is structurally unsustainable. Negative free cash flow of -$68M annually implies 18-24 month cash runway, requiring dilutive equity financing within 12-24 months. ChatGPT: Operating margin of -387.6% and net margin of -385.9% show the business is still far from profitable. Free cash flow of -$236.17M and operating cash flow of -$216.25M imply heavy ongoing cash burn.
What is AUTL's revenue and growth?
Autolus Therapeutics plc reported revenue of $26.2M.
Does AUTL pay dividends?
Autolus Therapeutics plc does not currently pay dividends.
Where can I find AUTL SEC filings?
Official SEC filings for Autolus Therapeutics plc (CIK: 0001730463) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AUTL's EPS?
Autolus Therapeutics plc has a diluted EPS of $-0.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AUTL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Autolus Therapeutics plc has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AUTL stock overvalued or undervalued?
Valuation metrics for AUTL: ROE of -65.8% (sector avg: 15%), net margin of -273.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AUTL's AI grade for 2026?
Our dual AI analysis gives Autolus Therapeutics plc a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AUTL's free cash flow?
Autolus Therapeutics plc's operating cash flow is $-65.3M, with capital expenditures of $2.7M. FCF margin is -259.4%.
How does AUTL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -273.1% (avg: 12%), ROE -65.8% (avg: 15%), current ratio 5.80 (avg: 2).